Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dr Reddy's Laboratories has reported revenues of $420m for the second quarter of FY11, an increase of 2%, compared to $412m for the comparable period in 2010.
Subscribe to our email newsletter
Dr Reddy’s Laboratories has posted a net income of $64m for the Q2 FY11, or $0.4 per diluted share, compared to net income of $48.92m, or $0.3 per diluted share, for the comparable period in 2010.
Gross profit was $224m in Q2 FY11 at a margin of 53% to revenues versus 47% in Q2 FY10.
This change in gross margin is largely on account of contribution from new products of tacrolimus and amlodipine benazepril and one time inventory provisions of approximately $12m in the global generics segment in the corresponding quarter of previous year.
As a fully integrated pharmaceutical company, Dr Reddy’s Laboratories provides medicines through its three core businesses which are Pharmaceutical Services and Active Ingredients, comprising Active Pharmaceuticals and Custom Pharmaceuticals businesses; Global Generics, which includes branded and unbranded generics; and Proprietary Products, which includes New Chemical Entities (NCEs), differentiated formulations, and generic biopharmaceuticals.